Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells

Journal of Cellular Biochemistry

Volumn 112, Issue 1, 2011, Pages 341-353

  Grieco, Paolo ^a   Franco, Renato ^b   Bozzuto, Giuseppina ^c   Toccacieli, Laura ^c   Sgambato, Alessandro ^b   Marra, Monica ^b   Zappavigna, Silvia ^b   Migaldi, Mario ^e   Rossi, Giulio ^e   Striano, Stefano ^b   Marra, Luigi ^b   Gallo, Luigi ^b   Cittadini, Achille ^d   Botti, Gerardo ^b   Novellino, Ettore ^c   Molinari, Agnese ^c   Budillon, Alfredo ^b   Caraglia, Michele ^f  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Prognostic marker; Prostate cancer; Urotensin II receptor

Indexed keywords

FOCAL ADHESION KINASE; INTEGRIN; MESSENGER RNA; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; URANTIDE; UROTENSIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PATIENT; CARCINOGENESIS; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG EFFECT; ENZYME PHOSPHORYLATION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; RNA, MESSENGER; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 78651306525     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22933     Document Type: Article

References (44)

1. Albertsen PC, Hanley JA, Fine J. 2005. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA 293:2095-2101. (Pubitemid 40617061)
2. Albini A, Iwamoto Y, Kleinman HK, Martin GR, Aaronson SA, Kozlowski JM, McEwan RN. 1987. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 47:3239-3245.
3. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA. 1999. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401:282-286.
4. Asano T, Aoyagi M, Hirakawa K, Ikawa Y. 1984. Effect of endothelin-1 as growth factor on a human glioma cell line, its characteristic promotion of DNA synthesis. J Neurooncol 18:1-7.
5. Bachmeier BE, Nerlich AG, Lichtinghagen R, Sommerhoff CP. 2001. Matrix metalloproteinases (MMPs) in breast cancer cell lines of different tumorigenicity. Anticancer Res 21:3821-3828.
6. Camarda V, Song W, Marzolac E, Spagnol M, Guerrini R, Salvadori S, Regoli D, Thompson JP, Rowbotham DJ, Behm DJ, Douglas SA, Calo G, Lambert DG. 2004. Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur J Pharmacol 498:83-86.
7. Carotenuto A, Grieco P, Novellino E, Rovero P. 2004. Urotensin-II receptor peptide agonists. Med Res Rev 24:577-588.
8. Clark EA, Golub TR, Lander ES, Hynes RO. 2000. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406:532-535.
9. Colone M, Calcabrini A, Toccacieli L, Bozzuto G, Stringaro A, Gentile M, Cianfriglia M, Ciervo A, Caraglia M, Budillon A, Meo G, Arancia G, Molinari A. 2008. The multidrug transporter P-glycoprotein. A mediator of melanoma invasion? J Invest Dermatol 128:957-971.
10. Douglas SA, Ohlstein EH. 2000. Human urotensin II the most potent mammalian vasoconstrictor identified to date as a therapeutic target for the management of cardiovascular disease. Trends Cardiovasc Med 10:229-237.
11. Egevad L. 2008. Recent trends in Gleason grading of prostate cancer II prognosis reproducibility and reporting. Anal Quant Cytol Histol 30:254-260.
12. Facchini G, Caraglia M, Morabito A, Marra M, Piccirillo MC, Bochicchio AM, Striano S, Marra L, Nasti G, Ferrari E, Leopardo D, Vitale G, Gentilini D, Tortoriello A, Catalano A, Budillon A, Perrone F, Iaffaioli RV. 2010. Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: Phase I ZANTE trial. Cancer Biol Ther [Epub ahead of print].
13. Franco R, Cantile M, Scala S, Catalano E, Cerrone M, Scognamiglio G, Pinto A, Chiofalo MG, Caracò C, Anniciello AM, Abbruzzese A, Caraglia M, Botti G. 2010. Histomorphologic parameters and CXCR4 mRNA and protein expression in sentinel node melanoma metastasis are correlated to clinical outcome. Cancer Biol Ther 9:423-429.
14. Gardiner SM, March JE, Kemp PA, Bennett T. 2001. Depressor and regionallyselective vasodilator effects of human and rat urotensin II conscious rats. Br J Pharmacol 132:1625-1629.
15. Gleason DF, Mellinger GT. 1974. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 11:58-64.
16. Greene F, Page D, Fleming I, Fritz A, Bach C, Haller D, Morrow M. 2002. American Joint Committee on Cancer Staging Manual (6th ed.) Springer, New York.
17. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. 2003. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232-1237.
18. Hauck CR, Hsia DA, Schlaepfer DD. 2002. The focal adhesion kinase-A regulator of cell migration and invasion. IUBMB Life 53:2115-2119.
19. Hehlgans S, Haase M, Cordes N. 2007. Signalling via integrins: Implications for cell survival and anticancer strategies. Biochim Biophys Acta 1775:163-180.
20. Holmboe ES, Concato J. 2000. Treatment decisions for localized prostate cancer, asking men what's important. J Gen Intern Med 15:694-701.
21. Hsia DA, Mitra SK, Hauck CR, Streblow DN, Nelson JA, Ilic D, Huang S, Li E, Nemerow GR, Leng J, Spencer KS, Cheresh DA, Schlaepfer DD. 2003. Differential regulation of cell motility and invasion by FAK. J Cell Biol 160:753-767.
22. Ishibashi O, Mori Y, Kurokawa T, Kumegawa M. 1999. Breast cancer cells express cathepsins B and L but not cathepsins K or H. Cancer Biochem Biophys 17:69-78.
23. Johansson JE, Holmberg L, Johansson S, Bergström R, Adami HO. 1997. Fifteen year survival in prostate cancer: A prospective population-based study in Sweden. JAMA 277:467-471.
24. KusuharaM, Yamaguchi K, Nagasaki K, Hayashi C, Suzaki A, Hori S, Handa S, Nakamura Y, Abe K. 1990. Production of endothelin in human cancer cell lines. Cancer Res 50:3257-3261.
25. Lavecchia A, Cosconati S, Novellino E. 2005. Architecture of the human urotensin II receptor, comparison of the binding domains of peptide and nonpeptide urotensin II agonists. J Med Chem 48:2480-2492.
26. Lokeshwar BL. 1999. MMP inhibition in prostate cancer. Ann NY Acad Sci 878:271-289.
27. Marra M, Santini D, Meo G, Vincenzi B, Zappavigna S, Baldi A, Rosolowski M, Tonini G, Loeffler M, Lupu R, Addeo SR, Abbruzzese A, Budillon A, Caraglia M. 2009. Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells. Int J Cancer 125:2004-2013.
28. Narumiya S, Tanji M, Ishizaki T. 2009. Rho signaling ROCK and mDia1 in transformation metastasis and invasion. Cancer Metastasis Rev 28:65-76.
29. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. 1997. Combination of prostate-specific antigen clinical stage and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. JAMA 277:1445-1451.
30. Patacchini R, Santicioli P, Giuliani S, Grieco P, Novellino E, Rovero P, Maggi CA. 2003. Urantide, an ultrapotent urotensin II antagonist peptide in the rat aorta. Br J Pharmacol 140:1155-1158.
31. Pertz O, Hodgson L, Klemke RL, Hahn KM. 2006. Spatio-temporal dynamics of RhoA activity in migrating cells. Nature 440:1069-1072.
32. Quinn DI, Henshall SM, Sutherland RL. 2005. Molecular markers of prostate cancer outcome. Eur J Cancer 41:858-887.
33. Ren X, Kiosses WB, Sieg DJ, Otey CA, Schlaepfer DD, Schwartz MA. 2000. Focal adhesion kinase suppresses Rho activity to promote focal adhesion turnover. J Cell Sci 113:3673-3678.
34. Sgambato A, Puglisi MA, Errico F, Rafanelli F, Boninsegna A, Rettino A, Genovese G, Coco C, Gasbarrini A, Cittadini A. 2010. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: Implications for its detection. J Cell Physiol 224:234-241.
35. Shichiri M, Hirata Y, Nakajima T, Ando K, Imai T, Yanagisawa M, Masaki T, Marumo F. 1991. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest 87:1867-1871.
36. Sone M, Takahashi K, Totsune K, Murakami O, Arihara Z, Satoh F, Mouri T, Shibahara S. 2000. Expression of endothelin-1 and endothelin receptors in cultured human glioblastoma cells. J Cardiovasc Pharmacol 26:S390-S392.
37. Takahashi K, Hara E, Murakami O, Totsune K, Sone M, Satoh F, Kumabe T, Tominaga T, Kayama T, Yoshimoto T, Shibahara S. 1998a. Production and secretion of endothelin-1 by cultured choroid plexus carcinoma cells. J Cardiovasc Pharmacol 31:S367-S369.
38. Takahashi K, Nakayama M, Shibahara S. 1998b. Production and secretion of neuropeptides by nervous system tumors. Cancer J 11:237-241.
39. Takahashi K, Yoshinoya A, Murakami O, Totsune K, Shibahara S. 2000. Production and secretion of two vasoactive peptides adrenomedullin and endothelin-1 by cultured human adrenocortical carcinoma cells. Peptides 21:251-256.
40. Takahashi K, Totsune K, Murakami O, Shibahara S. 2001. Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides 22:1175-1179.
41. Takahashi K, Totsune K, Murakami O, Arihara Z, Noshiro T, Hayashi Y, Shibahara S. 2003. Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. Peptides 24:301-306.
42. Taylor JM, Macklem MM, Parsons JT. 1999. Cytoskeletal changes induced by GRAF the GTPase regular associated with focal adhesion kinase are mediated by Rho. J Cell Sci 112:231-242.
43. Wolf K, Mazo I, Leung H, Engelke K, von Andrian UH, Deryugina EI, Strongin AY, Bröcker EB, Friedl P. 2003. Compensation mechanism in tumor cell migration: Mesenchymal-Amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 160:267-277.
44. Zheng DQ, Woodward AS, FornaroM, Tallini G, Languino LR. 1999. Prostatic carcinoma cell migration via aVb3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59:1655-1664.